We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Rheumatoid arthritis patients who are on standard methotrexate therapy may benefit from the addition of the biologic treatment, ENBREL (etanercept), according to new data from a one-year, open-label extension of the international TEMPO trial.
The ZLB Behring Foundation for Research and Advancement of Patient Health today announced that it is accepting grant applications for programs designed to benefit the bleeding disorders community in the United States.
La Jolla Pharmaceutical announced that its Marketing Authorization Application has been accepted for review by the European Medicines Agency for potential approval to market Riquent, its drug candidate for lupus renal disease, in the European Union.
Sirion Therapeutics, Inc., an ophthalmic-focused pharmaceutical company, announced today that it has reached an exclusive licensing agreement with Senju Pharmaceutical Co., Ltd. of Japan for the U.S. rights to develop and market a topical ophthalmic emulsion containing the steroid compound difluprednate for the treatment of inflammatory eye diseases.
The FDA's move to harmonize its approach to risk management with its European counterparts could prove too expensive for many pharmaceutical companies to handle, potentially leading some products to be withdrawn from the market, an industry consultant said.
A prominent U.S. senator has asked the FTC to launch an antitrust investigation into whether Merck is offering rebates to major health
insurers that agree to adjust drug copays so it will be cheaper to buy Merck's cholesterol drug Zocor than the generic equivalent.